Most psychedelic use happens outside hospitals. Here’s why community-led, non-clinical models matter—and how DMV patients can navigate access, safety, and support today.

A University of Georgia analysis of 20M+ responses finds a 7% drop in health-related absences where medical cannabis is accessible, with strongest effects in physical jobs.

A new driving-simulator study found no intoxication or cognitive impairment from 15–1,500 mg CBD. Here’s what that means for patients, drivers, and DMV consumers.

Disabled and autistic participants face distinct physiological and sensory needs during psychedelic work. Here’s how to make ceremonies safer—and what DMV readers should know.

What science says about terpenes, how they shape cannabis effects with cannabinoids, and what this means for patients and consumers in DC, Maryland and Virginia.

Psychedelic Science Review reports a rapid rise in psilocybin interest, with 100+ clinical trials since the early 2000s and recent studies signaling strong therapeutic potential.

HRSA logged 59 comments on training and outpatient delivery models for potential FDA‑approved psychedelic therapies. We unpack what’s being explored, plus why credentials, clinics, and costs matter.

A look at non‑drug “technodelics” like mirrored chambers, strobe light journeys, and full‑body pods—and what early research suggests about benefits, safety, and limits.